NHL: Follicular Lymphoma Epidemiology and Patient-Based Market 2016-2025 - Market will Continue to Grow Despite the Entry of Biosimilars and Generics - Research and Markets

DUBLIN, August 16, 2016 /PRNewswire/ --

Research and Markets has announced the addition of the "Nhl: Follicular Lymphoma: Epidemiology and Patient-Based Market Forecasts, Treatment Algorithm, and Marketed and Pipeline Drug Analysis" report to their offering.

The follicular lymphoma (FL) market will continue to grow during 2016-25, despite the entry of biosimilars and generics, due to an increase in disease incidence and the launch of new pipeline therapies.

This report addresses the following questions:

- What will be driving the growth of the FL market during 2016-25?
- Which market will be the most lucrative and which will experience fastest growth?
- Which branded therapies will have the largest impact on the FL market?
- When will generic and biosimilar therapies enter the market and what impact will they have on revenues?

Key Topics Covered:

FORECAST: FOLLICULAR LYMPHOMA

- Copanlisib
- Duvelisib
- Gazyva (obinutuzumab)
- Imbruvica (ibrutinib)
- Revlimid (lenalidomide)
- Rituxan (rituximab)
- Treanda (bendamustine)
- Zevalin (ibritumomab tiuxetan)
- Zydelig (idelalisib)
- Primary Research Methodology

TREATMENT: FOLLICULAR LYMPHOMA

- Primary Research Methodology
- Disease Definition and Diagnosis
- Patient Segmentation
- Country Treatment Trees
- Current Treatment Options
- Prescribing Trends

EPIDEMIOLOGY: FOLLICULAR LYMPHOMA

- Disease Background
- Sources and Methodology
- Forecast: NHL Overall
- Forecast: NHL Subtypes (incl. DLBCL, FL, and MCL)
- Epidemiologist Insight
- Strengths and Limitations

MARKETED DRUGS: FOLLICULAR LYMPHOMA

- Product profile: Gazyva
- Product profile: Rituxan
- Product profile: Treanda
- Product profile: Zevalin
- Product profile: Zydelig

PIPELINE: FOLLICULAR LYMPHOMA

- Product profile (late stage): Arzerra
- Product profile (late stage): Imbruvica
- Product profile (late stage): Revlimid
- Product profile (late stage): copanlisib
- Product profile (late stage): duvelisib

For more information about this report visit http://www.researchandmarkets.com/research/cdkhw5/nhl_follicular

Related Topics: Lymphoma Drugs

Media Contact:

Research and Markets
Laura Wood, Senior Manager
[e-mail]

For E.S.T Office Hours Call [phone]
For U.S./CAN Toll Free Call [phone]
For GMT Office Hours Call [phone]

U.S. Fax: [phone]
Fax (outside U.S.): [phone]